GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Clinical trials for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy shot for dry AMD shows promise in early trial
Disease control TerminatedThis study tested a single injection of a gene therapy called GT005 in 98 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. The goal was to see if the treatment could slow the growth of damaged areas in the eye and c…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy shot for dry AMD shows promise but trial halted early
Disease control TerminatedThis study tested a single injection of GT005, a gene therapy, in 255 people with geographic atrophy from dry age-related macular degeneration. The goal was to see if it could slow the growth of blind spots in the eye. The trial was terminated early, so we have less data than hop…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental gene injection targets dry AMD
Disease control TerminatedThis early-stage trial tested a gene therapy called GT005 for dry age-related macular degeneration (AMD), a leading cause of vision loss. The therapy delivers a working gene to the retina via a single injection. The study enrolled 56 people and focused on safety and dosing, but w…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Eye drug trial halted: could danicopan still slow blind spots?
Disease control TerminatedThis Phase 2 study tested an oral drug called danicopan in 365 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. Participants took different doses of danicopan or a placebo for up to 104 weeks to see if it could slow…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:21 UTC